Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Cerenis Therapeutics raises funds to develop HDL therapies

July 26, 2010

Almirall and Pfizer join to commercialize Conbriza for osteoporosis in Spain

July 26, 2010

EMA provides update on benefit-to-risk review of Avandia, Avandamet and Avaglim

July 26, 2010

Sirtris Pharmaceuticals describes new SIRT modulators

July 23, 2010

CP-404 successfully completes pilot phase I study for obesity

July 23, 2010

Tarsa advances phase III oral calcitonin trial in postmenopausal osteoporosis

July 23, 2010

Repros Therapeutics to start low-dose study of Proellex

July 23, 2010

Insulin degludec improves glucemic control in phase II trials in type 1 and 2 diabetes

July 23, 2010

GSK suspends enrollment in TIDE trial at FDA's request

July 22, 2010

Sirtris Pharmaceuticals describes new sirtuin modulators

July 22, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...